AdvisorShares Psychedelics ETF(PSIL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
AdvisorShares Psychedelics ETF
PSIL.US
News
View More

Neurocrine Biosciences Reports INGREZZA Achieves Higher VMAT2 Occupancy Than AUSTEDO XR in Head-to-Head Study

Neurocrine Biosciences Inc. has reported the first head-to-head study comparing VMAT2 occupancy between INGREZZA and AUSTEDO XR. Using PET imaging, the study found that INGREZZA achieved higher VMAT2 occupancy at therapeutic doses (83% for 40 mg and 92% for 80 mg) compared to AUSTEDO XR (54% for 24 mg and 70% for 48 mg). These results are significant for treating involuntary movement disorders such as tardive dyskinesia and Huntington’s disease chorea. The findings were presented at a recent meeting.

Reuters·
US
NBIX
-0.72%
Reuters·
US
NBIX
-0.72%

Avadel Shareholders Approve Acquisition by Alkermes

Avadel Pharmaceuticals shareholders have approved the acquisition by Alkermes plc, with 97.41% voting in favor. The resolutions related to the transaction received strong support at the scheme meeting. Additionally, shareholders approved the compensatory arrangements for the company’s named executive officers in connection with the acquisition.

Reuters·
US
ALKS
+1.31%
US
AVDL
0.00%
Reuters·
US
ALKS
+1.31%
US
AVDL
0.00%

FDA Grants Breakthrough Therapy Designation to Alkermes' Alixorexton for Narcolepsy Type 1

Alkermes plc has received Breakthrough Therapy designation from the FDA for its investigational drug alixorexton, aimed at treating narcolepsy type 1. This designation follows positive results from phase 1 and phase 2 clinical trials, including the Vibrance-1 study, which demonstrated significant improvements in wakefulness. Alkermes plans to move alixorexton into phase 3 development in Q1 2026, aiming to expedite the drug's development and review process.

Reuters·
US
ALKS
+1.31%
Reuters·
US
ALKS
+1.31%

FDA Lifts Clinical Hold on GH Research's GH001, Allowing U.S. Trials

GH Research plc announced that the FDA has lifted the clinical hold on its Investigational New Drug Application for GH001, allowing U.S. subject enrollment. This regulatory clearance paves the way for a global Phase 3 program targeting treatment-resistant depression, with initiation planned for 2026. The company aims to align with the FDA on the Phase 3 program design to replicate successful Phase 2b trial results.

Reuters·
US
GHRS
+0.18%
Reuters·
US
GHRS
+0.18%

Neurocrine's movement disorder treatment fails late-stage trial

Neurocrine Biosciences announced that its drug valbenazine failed to meet the primary endpoint in a late-stage trial for dyskinetic cerebral palsy. The 14-week study showed no significant improvement in involuntary movements compared to a placebo. Shares fell about 1% in extended trading. The company plans to present full results at a future scientific meeting. Valbenazine is already approved in the U.S. for tardive dyskinesia and chorea associated with Huntington’s disease.

Reuters·
US
NBIX
-0.72%
Reuters·
US
NBIX
-0.72%
© 2026 Longbridge｜Disclaimer